Testing ALK201 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your tumor is measurable on a scan.
- Your cancer has spread or cannot be removed by surgery.
- You are in generally good health (able to do daily activities without help).
- You agree to use birth control for 6 months after the last dose.
- You have not had a live vaccine in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a new injectable drug called ALK-N001 in people with advanced solid tumors that have stopped responding to standard treatment. It's for various cancers including lung, breast, ovarian, cervical, pancreatic, liver, and esophageal cancer. The goal is to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This study tests a new drug called ALK201 combined with another drug (ivonescimab) to see if they are safe and help people with a type of lung cancer called squamous non-small cell lung cancer. If you join, you may receive the combination treatment and be closely monitored.
This study tests a new combination cancer medicine (ALK202) for non-small cell lung cancer that hasn't responded to standard treatments. The goal is to see if this drug combination shrinks tumors and is safe to take.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.